The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper

Abstract

Background One year after the declaration of the coronavirus disease 2019 (COVID-19) pandemic by the World Health Organization (WHO) and despite the implementation of mandatory physical barriers and social distancing, humanity remains challenged by a long-lasting and devastating public health crisis.

Management Non-pharmacological interventions (NPIs) are efficient mitigation strategies. The success of these NPIs is dependent on the approval and commitment of the population. The launch of a mass vaccination program in many countries in late December 2020 with mRNA vaccines, adenovirus-based vaccines, and inactivated virus vaccines has generated hope for the end of the pandemic.

Current Issues The continuous appearance of new pathogenic viral strains and the ability of vaccines to prevent infection and transmission raise important concerns as we try to achieve community immunity against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and its variants. The need of a second and even third generation of vaccines has already been acknowledged by the WHO and governments.

Perspectives There is a critical and urgent need for a balanced and integrated strategy for the management of the COVID-19 outbreaks organized on three axes: (1) Prevention of the SARS-CoV-2 infection, (2) Detection and early diagnosis of patients at risk of disease worsening, and (3) Anticipation of medical care (PDA).

Conclusion The “PDA strategy” integrated into state policy for the support and expansion of health systems and introduction of digital organizations (i.e., telemedicine, e-Health, artificial intelligence, and machine-learning technology) is of major importance for the preservation of citizens' health and life world-wide.

Keywords

COVID-19 - SARS-CoV-2 - pandemic - thrombosis - health care systems

^* Scientific Reviewer Committee Members: Gregory Y. H. Lip, Michael Makris, Sam Schulman, Wolfgang Siess, Christian Weber

Publikationsverlauf

Eingereicht: 04. Mai 2021

Angenommen: 17. Juni 2021

Accepted Manuscript online:
24. Juni 2021

Artikel online veröffentlicht:
20. Juli 2021

• References

• 1 https://solidarites-sante.gouv.fr/IMG/pdf/avis_conseil_scientifique_6_mai_2021.pdf andhttps://www.lemonde.fr/podcasts/article/2021/06/30/le-variant-delta-peut-il-declencher-une-quatrieme-vague_6086296_5463015.html
• 2 Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ 2021; 372 (579) n579
• 3 Garcia-Beltran WF, Lam EC, St Denis K. et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 2021; 184 (09) 2372-2383.e9
• 4 Paul P, France AM, Aoki Y. et al. Genomic Surveillance for SARS-CoV-2 variants circulating in the united states, December 2020-May 2021. MMWR Morb Mortal Wkly Rep 2021; 70 (23) 846-850
• 5 Johanna N, Citrawijaya H, Wangge G. Mass screening vs lockdown vs combination of both to control COVID-19: a systematic review. J Public Health Res 2020; 9 (04) 2011
• 6 Riccardo F, Ajelli M, Andrianou XD. et al; COVID-19 working group. Epidemiological characteristics of COVID-19 cases and estimates of the reproductive numbers 1 month into the epidemic, Italy, 28 January to 31 March 2020. Euro Surveill 2020; 25 (49) 2000790
• 7 Carrat F, Touvier M, Severi G. et al; SAPRIS study group. Incidence and risk factors of COVID-19-like symptoms in the French general population during the lockdown period: a multi-cohort study. BMC Infect Dis 2021; 21 (01) 169
• 8 Gaudart J, Landier J, Huiart L. et al. Factors associated with the spatial heterogeneity of the first wave of COVID-19 in France: a nationwide geo-epidemiological study. Lancet 2021; 6 (04) E222-E231
• 9 Timelli L, Girardi E. Effect of timing of implementation of containment measures on Covid-19 epidemic. The case of the first wave in Italy. PLoS One 2021; 16 (01) e0245656
• 10 Denford S, Morton KS, Lambert H. et al. Understanding patterns of adherence to COVID-19 mitigation measures: a qualitative interview study. J Public Health 2021;
• 11 Raude J, Lecrique JM, Lasbeur L. et al. Determinants of preventive behaviors in response to the COVID-19 pandemic in France: comparing the sociocultural, psychosocial, and social cognitive explanations. Front Psychol 2020; 11: 584500
• 12 https://univ-droit.fr/actualites-de-la-recherche/appels/34809-covid-19-constitutional-political-and-social-threats-and-challenges-in-france-and-the-united-kingdom Accessed June 27, 2021
• 13 SciencePo.. OSC papers. Accessed June 27, 2021 at: https://spire.sciencespo.fr/hdl:/2441/6vv2fug6nb8t29ilm995n9hbnh/resources/op-2020-1.pdf
• 14 Contreras S, Dehning J, Loidolt M. et al. The challenges of containing SARS-CoV-2 via test-trace-and-isolate. Nat Commun 2021; 12 (01) 378
• 15 Bendavid E, Oh C, Bhattacharya J, Ioannidis JPA. Assessing mandatory stay-at-home and business closure effects on the spread of COVID-19. Eur J Clin Invest 2021; 51 (04) e13484
• 16 Atlani-Duault L, Chauvin F, Yazdanpanah Y. et al. France's COVID-19 response: balancing conflicting public health traditions. Lancet 2020; 396 (10246) 219-221
• 17 Milman O, Yelin I, Aharony N. et al. Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals. Nat Med 2021;
• 18 European Commission.. Commission sets out key actions for a united front to beat COVID-19. Accessed June 27, 2021 at: https://ec.europa.eu/commission/presscorner/detail/en/IP_21_143
• 19 Lazarus JV, Ratzan SC, Palayew A. et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med 2021; 27 (02) 225-228
• 20 Brandt EJ, Rosenberg J, Waselewski ME. et al. National study of youth opinions on vaccination for COVID-19 in the U.S. J Adolesc Health 2021; 68 (05) 869-872
• 21 Schmelz K, Bowles S. Overcoming COVID-19 vaccination resistance when alternative policies affect the dynamics of conformism, social norms, and crowding out. Proc Natl Acad Sci U S A 2021; 118 (25) e2104912118
• 22 Gavi.. COVID-19 vaccines in development. Accessed June 27, 2021 at: https://www.gavi.org/sites/default/files/covid/covid-19-vaccines-development-phases.png
• 23 Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med 2021; 27 (02) 205-211
• 24 Baden LR, El Sahly HM, Essink B. et al; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384 (05) 403-416
• 25 Polack FP, Thomas SJ, Kitchin N. et al; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383 (27) 2603-2615
• 26 Logunov DY, Dolzhikova IV, Shcheblyakov DV. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021; 397 (10275): 671-681
• 27 Angelis A, Baltussen R, Tervonen T. The need for novel approaches in assessing the value of COVID-19 vaccines. Am J Public Health 2021; 111 (02) 205-208
• 28 Oxfam.. Small group of rich nations have bought up more than half the future supply of leading COVID-19 vaccine contenders. Accessed June 27, 2021 at: https://www.oxfam.org/fr/node/14233
• 29 UN News.. Low-income countries have received just 0.2 per cent of all COVID-19 shots given. Accessed June 27, 2021 at: https://news.un.org/en/story/2021/04/1089392
• 30 Our World in Data.. Coronavirus (COVID-19) vaccinations. Accessed June 27, 2021 at: https://ourworldindata.org/covid-vaccinations
• 31 Emanuel EJ, Luna F, Schaefer GO, Tan KC, Wolff J. Enhancing the WHO's proposed framework for distributing COVID-19 vaccines among countries. Am J Public Health 2021; 111 (03) 371-373
• 32 WHO.. Statement on the fifth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic. Accessed June 27, 2021 at: https://www.who.int/news/item/30-10-2020-statement-on-the-fifth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic
• 33 Foreign Policy.. Vaccine nationalism harms everyone and protects no one. Accessed June 27, 2021 at: https://foreignpolicy.com/2021/02/02/vaccine-nationalism-harms-everyone-and-protects-no-one/
• 34 Statista.. Impact of the coronavirus pandemic on the global economy - statistics & facts. Accessed June 27, 2021 at: https://www.statista.com/topics/6139/covid-19-impact-on-the-global-economy/
• 35 ICC.. Study shows vaccine nationalism could cost rich countries US$4.5 trillion. Accessed June 27, 2021 at: https://iccwbo.org/media-wall/news-speeches/study-shows-vaccine-nationalism-could-cost-rich-countries-us4-5-trillion/
• 36 WHO.. Statement on the sixth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic. Accessed June 27, 2021 at: https://www.who.int/news/item/15-01-2021-statement-on-the-sixth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic
• 37 Callaway E. Fast-spreading COVID variant can elude immune responses. Nature 2021; 589 (7843): 500-501
• 38 Callaway E. The coronavirus is mutating - does it matter?. Nature 2020; 585 (7824): 174-177
• 39 Hacisuleyman E, Hale C, Saito Y. et al. Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med 2021; 384 (23) 2212-2218
• 40 Long SW, Olsen RJ, Christensen PA. et al. Sequence analysis of 20,453 severe acute respiratory syndrome coronavirus 2 genomes from the Houston Metropolitan area identifies the emergence and widespread distribution of multiple isolates of all major variants of concern. Am J Pathol 2021; 191 (06) 983-992
• 41 Outbreak.info.. Accessed June 27, 2021 at: https://outbreak.info/situation-reports
• 42 Huang SW, Wang SF. SARS-CoV-2 entry related viral and host genetic variations: implications on COVID-19 severity, immune escape, and infectivity. Int J Mol Sci 2021; 22 (06) 3060
• 43 Gómez CE, Perdiguero B, Esteban M. Emerging SARS-CoV-2 variants and impact in global vaccination programs against SARS-CoV-2/COVID-19. Vaccines (Basel) 2021; 9 (03) 243
• 44 Fergie J, Srivastava A. Immunity to SARS-CoV-2: lessons learned. Front Immunol 2021; 12: 654165
• 45 Fourati S, Decousser JW, Khouider S. et al. Novel SARS-CoV-2 variant derived from Clade 19B, France. Emerg Infect Dis 2021; 27 (05) 1540-1543
• 46 WHO.. SARS-CoV-2 mink-associated variant strain – Denmark. Accessed June 27, 2021 at: https://www.who.int/csr/don/06-november-2020-mink-associated-sars-cov2-denmark/en/
• 47 Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020; 181 (02) 281.e6-292.e6
• 48 Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data - from vision to reality. Euro Surveill 2017; 22 (13) 30494
• 49 Shajahan A, Supekar NT, Gleinich AS, Azadi P. Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. Glycobiology 2020; 30 (12) 981-988
• 50 Collier DA, De Marco A, Ferreira IATM. et al; CITIID-NIHR BioResource COVID-19 Collaboration; COVID-19 Genomics UK (COG-UK) Consortium. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature 2021; 593 (7857): 136-141
• 51 Madhi SA, Baillie V, Cutland CL. et al; NGS-SA Group; Wits-VIDA COVID Group. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med 2021; 384 (20) 1885-1898
• 52 Steuwer B, Jamrozik E, Eyal N. Prioritizing second-generation SARS-CoV-2 vaccines through low-dosage challenge studies. Int J Infect Dis 2021; 105: 307-311
• 53 Callaway E, Ledford H. How to redesign COVID vaccines so they protect against variants. Nature 2021; 590 (7844): 15-16
• 54 EMA. COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets. Accessed June 27, 2021 at: https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots
• 55 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021; 384 (22) 2092-2101
• 56 CDC.. Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine. Accessed June 27, 2021 at: https://www.cdc.gov/media/releases/2021/s0413-JJ-vaccine.html
• 57 EMA.. COVID-19 Vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. Accessed June 27, 2021 at: https://www.ema.europa.eu/en/news/covid-19-vaccine-janssen-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood
• 58 Schultz NH, Sørvoll IH, Michelsen AE. et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021; 384 (22) 2124-2130
• 59 Pottegård A, Lund LC, Karlstad Ø. et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ 2021; 373 (1114): n1114
• 60 Thiele T, Ulm L, Holtfreter S. et al. Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2. Blood 2021;
• 61 ISTH.. ISTH interim guidance for the diagnosis and treatment on vaccine-induced immune thrombotic thrombocytopenia (updated 20 April, 2021). Accessed June 27, 2021 at: https://cdn.ymaws.com/www.isth.org/resource/resmgr/ISTH_VITT_Guidance_2.pdf
• 62 Elalamy I, Gerotziafas G, Alamowitch S. et al. SARS-CoV-2 vaccine and thrombosis: expert opinions. Thromb Haemost 2021;
• 63 Carli G, Nichele I, Ruggeri M, Barra S, Tosetto A. Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine. Intern Emerg Med 2021; 16 (03) 803-804
• 64 Jiménez D, García-Sanchez A, Rali P. et al. Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Chest 2021; 159 (03) 1182-1196
• 65 Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Res Pract Thromb Haemost 2020; 4 (07) 1178-1191
• 66 Roubinian NH, Dusendang JR, Mark DG. et al. Incidence of 30-day venous thromboembolism in adults tested for SARS-CoV-2 infection in an integrated health care system in Northern California. JAMA Intern Med 2021; 181 (07) 997-1000
• 67 Grasselli G, Greco M, Zanella A. et al; COVID-19 Lombardy ICU Network. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med 2020; 180 (10) 1345-1355
• 68 NICE.. COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE guideline [NG188]. https://www.nice.org.uk/GUIDANCE/ng188 Accessed June 27, 2021
• 69 Ledford H. Could mixing COVID vaccines boost immune response?. Nature 2021; 590 (7846): 375-376
• 70 Phillips N. The coronavirus is here to stay - here's what that means. Nature 2021; 590 (7846): 382-384
• 71 World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance 13 March 2020. Accessed June 27, 2021 at: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected
• 72 Chauhan AJ, Wiffen LJ, Brown TP. COVID-19: A collision of complement, coagulation and inflammatory pathways. J Thromb Haemost 2020; 18 (09) 2110-2117
• 73 Terpos E, Ntanasis-Stathopoulos I, Elalamy I. et al. Hematological findings and complications of COVID-19. Am J Hematol 2020; 95 (07) 834-847
• 74 Menter T, Haslbauer JD, Nienhold R. et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Histopathology 2020; 77 (02) 198-209
• 75 Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis. EClinicalMedicine 2020; 29: 100639
• 76 Edler C, Schröder AS, Aepfelbacher M. et al. Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive 80 cases in Hamburg, Germany. Int J Legal Med 2020; 134 (04) 1275-1284
• 77 Calabrese F, Pezzuto F, Fortarezza F. et al. Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists. Virchows Arch 2020; 477 (03) 359-372
• 78 Spyropoulos AC, Cohen SL, Gianos E. et al; COVID‒19 Consortium Group. Validation of the IMPROVE-DD risk assessment model for venous thromboembolism among hospitalized patients with COVID-19. Res Pract Thromb Haemost 2021; 5 (02) 296-300
• 79 Gerotziafas GT, Catalano M, Colgan MP. et al; Scientific Reviewer Committee. Guidance for the management of patients with vascular disease or cardiovascular risk factors and COVID-19: position paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. Thromb Haemost 2020; 120 (12) 1597-1628
• 80 Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Higher mortality of ischaemic stroke patients hospitalized with COVID-19 compared to historical controls. Cerebrovasc Dis 2021; 50 (03) 326-331
• 81 Vaughan CJ, Cronin H, Ryan PM, Caplice NM. Obesity and COVID-19: A Virchow's triad for the 21st century. Thromb Haemost 2020; 120 (11) 1590-1593
• 82 Gerotziafas GT, Sergentanis TN, Voiriot G. et al. Derivation and validation of a predictive score for disease worsening in patients with COVID-19. Thromb Haemost 2020; 120 (12) 1680-1690
• 83 Ribas A, Sengupta R, Locke T. et al; AACR COVID-19 and Cancer Task Force. Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited. Cancer Discov 2021; 11 (02) 233-236
• 84 Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Atrial fibrillation and the risk of 30-day incident thromboembolic events, and mortality in adults ≥ 50 years with COVID-19. J Arrhythm 2020; 37 (01) 231-237
• 85 Zhu L, She ZG, Cheng X. et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab 2020; 31 (06) 1068.e3-1077.e3
• 86 GOV.UK.. COVID-19: review of disparities in risks and outcomes. Accessed June 27, 2021 at: https://www.gov.uk/government/publications/covid-19-review-of-disparities-in-risks-and-outcomes
• 87 Quiroz JC, Feng YZ, Cheng ZY. et al. Development and validation of a machine learning approach for automated severity assessment of COVID-19 based on clinical and imaging data: retrospective study. JMIR Med Inform 2021; 9 (02) e24572
• 88 Horgan D, Hackett J, Westphalen CB. et al. Digitalisation and COVID-19: the perfect storm. Biomed Hub 2020; 5 (03) 1341-1363
• 89 European Commission.. Accessed June 27, 2021 at: https://ec.europa.eu/health/sites/default/files/expert_panel/docs/015_access_healthservices_en.pdf
• 90 WHO.. Telemedicine. Accessed June 27, 2021 at: https://www.who.int/goe/publications/goe_telemedicine_2010.pdf
• 91 Thachil J, Tang N, Gando S. et al. Laboratory haemostasis monitoring in COVID-19. J Thromb Haemost 2020; 18 (08) 2058-2060
• 92 Wang L, Yang L, Bai L, Huang Z, Peng Y. Association between D-dimer level and chest CT severity score in patients with SARS-COV-2 pneumonia. Sci Rep 2021; 11 (01) 11636
• 93 Zamberg I, Manzano S, Posfay-Barbe K, Windisch O, Agoritsas T, Schiffer E. A mobile health platform to disseminate validated institutional measurements during the COVID-19 outbreak: utilization-focused evaluation study. JMIR Public Health Surveill 2020; 6 (02) e18668
• 94 Timmers T, Janssen L, Stohr J, Murk JL, Berrevoets MAH. Using eHealth to support COVID-19 education, self-assessment, and symptom monitoring in the Netherlands: observational study. JMIR Mhealth Uhealth 2020; 8 (06) e19822
• 95 European Commission.. Accessed June 27, 2021 at: https://ec.europa.eu/health/sites/default/files/ehealth/docs/2018_provision_marketstudy_telemedicine_en.pdf
• 96 Bourdrel T, Annesi-Maesano I, Alahmad B, Maesano CN, Bind MA. The impact of outdoor air pollution on COVID-19: a review of evidence from in vitro, animal, and human studies. Eur Respir Rev 2021; 30 (159) 200242
• 97 Ahmed F, Ahmed N, Pissarides C, Stiglitz J. Why inequality could spread COVID-19. Lancet Public Health 2020; 5 (05) e240
• 98 Bilal, Bashir MF, Benghoul M. et al. Environmental pollution and COVID-19 outbreak: insights from Germany. Air Qual Atmos Health 2020;
• 99 Brosemer K, Schelly C, Gagnon V. et al. The energy crises revealed by COVID: intersections of indigeneity, inequity, and health. Energy Res Soc Sci 2020; 68: 101661
• 100 Cordes J, Castro MC. Spatial analysis of COVID-19 clusters and contextual factors in New York City. Spat Spatio-Temporal Epidemiol 2020; 34: 100355
• 101 Rose-Redwood R, Kitchin R, Apostolopoulou E. et al. Geographies of the COVID-19 pandemic. Dialogues Hum Geogr 2020; 10 (02) 97-106
• 102 WHO.. Déclaration du Mécanisme COVAX sur les nouveaux variants du SARS-CoV-2. Accessed June 27, 2021 at: https://www.who.int/fr/news/item/08-02-2021-covax-statement-on-new-variants-of-sars-cov-2
• 103 WHO.. Global solidarity in the fight against COVID-19 takes centre stage during Regional Director's visit to Russian Federation. Accessed June 27, 2021 at: https://www.euro.who.int/en/about-us/regional-director/news/news/2020/09/global-solidarity-in-the-fight-against-covid-19-takes-centre-stage-during-regional-directors-visit-to-russian-federation
• 104 Human Rights Watch.. Urgently waive intellectual property rules for vaccine. Accessed June 27, 2021 at: https://www.hrw.org/news/2020/12/10/urgently-waive-intellectual-property-rules-vaccine
• 105 World Trade Organization.. Waiver from certain provisions of the trips agreement for the prevention, containment and treatment of COVID-19. Accessed June 27, 2021 at: https://docs.wto.org/dol2fe/Pages/SS/directdoc.aspx?filename=q:/IP/C/W669.pdf&Open=True
• 106 European Commission.. Improving pandemic preparedness and management. Accessed June 27, 2021 at: https://ec.europa.eu/info/sites/default/files/jointopinion_improvingpandemicpreparednessandmanagement_nov2020_0.pdf
• 107 Wang G, Luo FM, Liu D. et al; Sichuan & Wuhan Collaboration Research Group, and Sichuan Treatment Expert Group for COVID-19, China. Differences in the clinical characteristics and outcomes of COVID-19 patients in the epicenter and peripheral areas of the pandemic from China: a retrospective, large-sample, comparative analysis. BMC Infect Dis 2021; 21 (01) 206
• 108 Bordallo B, Bellas M, Cortez AF, Vieira M, Pinheiro M. Severe COVID-19: what have we learned with the immunopathogenesis?. Adv Rheumatol 2020; 60 (01) 50
• 109 Gencer S, Lacy M, Atzler D, van der Vorst EPC, Döring Y, Weber C. Immunoinflammatory, thrombohaemostatic, and cardiovascular mechanisms in COVID-19. Thromb Haemost 2020; 120 (12) 1629-1641
• 110 Levy E, Delvin E, Marcil V, Spahis S. Can phytotherapy with polyphenols serve as a powerful approach for the prevention and therapy tool of novel coronavirus disease 2019 (COVID-19)?. Am J Physiol Endocrinol Metab 2020; 319 (04) E689-E708
• 111 Lordan R. Notable developments for vitamin D amid the COVID-19 pandemic, but caution warranted overall: a narrative review. Nutrients 2021; 13 (03) 740
• 112 Drago F, Gozzo L, Li L, Stella A, Cosmi B. Use of enoxaparin to counteract COVID-19 infection and reduce thromboembolic venous complications: a review of the current evidence. Front Pharmacol 2020; 11: 579886
• 113 Billett HH, Reyes-Gil M, Szymanski J. et al. Anticoagulation in COVID-19: effect of enoxaparin, heparin, and apixaban on mortality. Thromb Haemost 2020; 120 (12) 1691-1699
• 114 D'Amato G, Acanfora L, Delli Paoli L, D'Amato M. Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations. Multidiscip Respir Med 2021; 16 (01) 748
• 115 Capell WH, Barnathan ES, Piazza G. et al. Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. Am Heart J 2021; 235: 12-23
• 116 Gonzalez-Ochoa AJ, Raffetto JD, Hernández AG. et al. Sulodexide in the treatment of patients with early stages of COVID-19: a randomized controlled trial. Thromb Haemost 2021; 121 (07) 944-954
• 117 Schulman S, Harenberg J. Anticoagulant treatment of COVID-19 as early as possible – sulodexide and perspectives. Thromb Haemost 2021; 121 (07) 849-853
• 118 Patell R, Chiasakul T, Bauer E, Zwicker JI. Pharmacologic thromboprophylaxis and thrombosis in hospitalized patients with COVID-19: a pooled analysis. Thromb Haemost 2021; 121 (01) 76-85
• 119 Bikdeli B, Madhavan MV, Gupta A. et al; Global COVID-19 Thrombosis Collaborative Group. Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research. Thromb Haemost 2020; 120 (07) 1004-1024
• 120 Dalekos GN, Stefos A, Georgiadou S. et al. Lessons from pathophysiology: use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19. Eur J Intern Med 2021; 88: 52-62
• 121 Naidu SB, Shah AJ, Saigal A. et al. The high mental health burden of “Long COVID” and its association with on-going physical and respiratory symptoms in all adults discharged from hospital. Eur Respir J 2021; 2004364: 2004364
• 122 Huang C, Huang L, Wang Y. et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397 (10270): 220-232
• 123 Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 2021; 594 (7862): 259-264
• 124 Vink M, Vink-Niese A. Could cognitive behavioural therapy be an effective treatment for long COVID and post COVID-19 fatigue syndrome? Lessons from the Qure study for Q-fever fatigue syndrome. Healthcare (Basel) 2020; 8 (04) 552
• 125 National Institutes of Health.. Coronavirus disease 2019 (COVID-19) treatment guidelines. Accessed May 17, 2020 at: https://www.covid19treatmentguidelines.nih.gov/
• 126 Patell R, Midha S, Kimani S. et al. Variability in institutional guidance for COVID-19-associated coagulopathy in the United States. Thromb Haemost 2020; 120 (12) 1725-1732
• 127 Cohoon KP, Mahé G, Tafur AJ, Spyropoulos AC. Emergence of institutional antithrombotic protocols for coronavirus 2019. Res Pract Thromb Haemost 2020; 4 (04) 510-517